Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)
An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)
Sponsor: Palleos Healthcare GmbH
Terminated
The trial stopped recruitment prematurely after a first planned interim analysis of the first 100 pCR results (given that a probability of less than 2.5% of meeting the primary endpoint was estimated).
Listed as NCT04770272, this PHASE2 trial focuses on Triple-negative Breast Cancer and remains terminated or withdrawn. Sponsored by Palleos Healthcare GmbH, it has been updated 10 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Dec 2024 — Feb 2026 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Dec 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Feb 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Palleos Healthcare GmbH
- Phaon Scientific GmbH
- Roche Pharma AG
- University Hospital Erlangen
- University Hospital, Essen
For direct contact, visit the study record on ClinicalTrials.gov .